Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447124 | 0.88 | GLA (0.59) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL9415751 | 0.82 | GLA (0.67) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL1446115 | 0.82 | L3MBTL1 (0.59) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7347977 | 0.81 | POLB (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL5778349 | 0.80 | L3MBTL1 (0.57) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7694058 | 0.80 | GLA (0.65) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL3404224 | 0.80 | L3MBTL1 (0.63) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL8395975 | 0.79 | ATM (0.65) | L3MBTL1LMNAALDH1A1HSD17B10RAB9A | |
| SCHEMBL10870 | 0.78 | L3MBTL1 (0.55) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL423653 | 0.78 | FKBP1A (0.56) | L3MBTL1TSHRPOLBGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109235-A1 | METHOD OF PRODUCING PYRIDONE DERIVATIVES | Shionogi & Co., Ltd (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9505783-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| EP-2412709-B1 | PROCESS FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-9260453-B2 | Method for producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8865907-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| EP-2412709-A1 | PROCESS FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | Shionogi & Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0392317-B1 | Benzimidazoles, drugs containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1996-01-03 | — | — | EP | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | L3MBTL1 4852/4885TSHR 2908/4885POLB 1322/4885 |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | L3MBTL1 4854/4885TSHR 2862/4885POLB 1394/4885 |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | L3MBTL1 4854/4885TSHR 2862/4885POLB 1394/4885 |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | L3MBTL1 1957/4885TSHR 19/4885POLB 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.